{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T02:53:49Z","timestamp":1774320829025,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T00:00:00Z","timestamp":1562025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In our clinical practice, women often report excess weight gain with infliximab (IFX) use. There are currently no studies investigating weight gain after antitumor necrosis factor therapy in patients with inflammatory bowel disease. The objective of this study was to evaluate the association of clinical factors, with a particular focus on sex and weight gain in patients with moderate to severe Crohn\u2019s disease (CD) or ulcerative colitis (UC) initiating IFX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data was extracted from ACCENT I, ACCENT II, ACT 1, and SONIC; included patients received IFX for induction or maintenance of remission of CD or UC. Patients treated with azathioprine (IFX 0 mg\/kg) were included as controls. Baseline demographics, clinical characteristics, and weight at each follow-up for the study duration were collected. In addition to descriptive statistics, adjusted mixed effects models were used to test the association between clinical variables and weight gain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 1273 patients included for analysis; the majority was white (91%), with CD (81%), and half of patients (50%) were women. Upon univariate analysis, IFX dose, African American race, diagnosis of CD, elevated C-reactive protein, and low hematocrit and albumin were associated with weight gain (P &amp;lt; 0.001). Upon adjusted analysis, sex was significantly associated with weight gain (P = 0.009), with women experiencing a lower percentage increase from baseline weight than men (3.9% increase vs 4.3% increase).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>When starting IFX, those with markers of severe disease and with a diagnosis of CD are likely to gain more weight. Adjusting for confounding variables, women actually gain less weight than men after IFX treatment, although this difference is not clinically relevant.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ibd\/izz133","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T18:22:53Z","timestamp":1562091773000},"page":"125-131","source":"Crossref","is-referenced-by-count":15,"title":["Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials"],"prefix":"10.1093","volume":"26","author":[{"given":"Kaci E","family":"Christian","sequence":"first","affiliation":[{"name":"University of Maryland School of Medicine, Division of Gastroenterology and Hepatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine M","family":"Russman","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Division of Gastroenterology and Hepatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhyan P","family":"Rajan","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Division of Gastroenterology and Hepatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik A","family":"Barr","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Department of Epidemiology and Public Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond K","family":"Cross","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Division of Gastroenterology and Hepatology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,7,2]]},"reference":[{"key":"2019121107072043100_CIT0001","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s disease cA2 study group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med."},{"key":"2019121107072043100_CIT0002","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med."},{"key":"2019121107072043100_CIT0003","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med."},{"key":"2019121107072043100_CIT0004","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology."},{"key":"2019121107072043100_CIT0005","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet."},{"key":"2019121107072043100_CIT0006","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology."},{"key":"2019121107072043100_CIT0007","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology."},{"key":"2019121107072043100_CIT0008","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med."},{"key":"2019121107072043100_CIT0009","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn\u2019s disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med."},{"key":"2019121107072043100_CIT0010","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","article-title":"Certolizumab pegol for active Crohn\u2019s disease: a placebo-controlled, randomized trial","volume":"9","author":"Sandborn","year":"2011","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2019121107072043100_CIT0011","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology."},{"key":"2019121107072043100_CIT0012","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"2019121107072043100_CIT0013","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2019121107072043100_CIT0014","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med."},{"key":"2019121107072043100_CIT0015","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn\u2019s disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology."},{"key":"2019121107072043100_CIT0016","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut."},{"key":"2019121107072043100_CIT0017","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","article-title":"Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials","volume":"30","author":"Lichtenstein","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"key":"2019121107072043100_CIT0018","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1572-0241.2007.01638.x","article-title":"Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn\u2019s disease","volume":"103","author":"Ainsworth","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"2019121107072043100_CIT0019","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","article-title":"Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis","volume":"65","author":"Fasanmade","year":"2009","journal-title":"Eur J Clin Pharmacol."},{"key":"2019121107072043100_CIT0020","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther."},{"key":"2019121107072043100_CIT0021","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/ard.2004.030452","article-title":"Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis","volume":"64","author":"Wolbink","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"2019121107072043100_CIT0022","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/art.30136","article-title":"Body mass index and clinical response to infliximab in rheumatoid arthritis","volume":"63","author":"Klaasen","year":"2011","journal-title":"Arthritis Rheum."},{"key":"2019121107072043100_CIT0023","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FTD.0b013e318180e300","article-title":"Infliximab pharmacokinetics in inflammatory bowel disease patients","volume":"30","author":"Ternant","year":"2008","journal-title":"Ther Drug Monit."},{"key":"2019121107072043100_CIT0024","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1210\/jc.2004-1222","article-title":"Impact of infliximab on serum leptin levels in patients with Crohn\u2019s disease","volume":"90","author":"Franchimont","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"2019121107072043100_CIT0025","author":"Stahl"},{"key":"2019121107072043100_CIT0026","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/jcph.220","article-title":"Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration","volume":"54","author":"Greenblatt","year":"2014","journal-title":"J Clin Pharmacol."},{"key":"2019121107072043100_CIT0027","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/509282a","article-title":"Policy: NIH to balance sex in cell and animal studies","volume":"509","author":"Clayton","year":"2014","journal-title":"Nature."},{"key":"2019121107072043100_CIT0028","doi-asserted-by":"crossref","first-page":"593039","DOI":"10.1155\/2012\/593039","article-title":"Weight gain and hair loss during anti-TNF therapy","volume":"2012","author":"Lutf","year":"2012","journal-title":"Int J Rheumatol."},{"key":"2019121107072043100_CIT0029","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1111\/j.1468-3083.2012.04571.x","article-title":"Body weight increment in patients treated with infliximab for plaque psoriasis","volume":"27","author":"Florin","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"2019121107072043100_CIT0030","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s10067-016-3244-7","article-title":"Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study","volume":"35","author":"Sfriso","year":"2016","journal-title":"Clin Rheumatol."},{"key":"2019121107072043100_CIT0031","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10067-011-1863-6","article-title":"Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis","volume":"31","author":"Brown","year":"2012","journal-title":"Clin Rheumatol."},{"key":"2019121107072043100_CIT0032","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1007\/s10620-017-4745-1","article-title":"Biologic agents are associated with excessive weight gain in children with inflammatory bowel disease","volume":"62","author":"Haas","year":"2017","journal-title":"Dig Dis Sci."},{"key":"2019121107072043100_CIT0033","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med."},{"key":"2019121107072043100_CIT0034","doi-asserted-by":"crossref","first-page":"i2156","DOI":"10.1136\/bmj.i2156","article-title":"BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants","volume":"353","author":"Aune","year":"2016","journal-title":"BMJ."},{"key":"2019121107072043100_CIT0035","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cgh.2012.02.004","article-title":"Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population","volume":"10","author":"Ha","year":"2012","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/1\/125\/31495459\/izz133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/1\/125\/31495459\/izz133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T19:39:53Z","timestamp":1663875593000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/26\/1\/125\/5527256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,7,2]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izz133","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,7,2]]}}}